OMICm Age (TruDiagnostic)
Epigenetic biological age estimation based on DNA methylation patterns across the genome.
Table of contents
Basic data
The OMICm Age test by TruDiagnostic estimates an individual’s biological age using DNA methylation data derived from a blood sample. It compares the methylation status of specific CpG sites across the genome to large reference populations, generating an age prediction that reflects cumulative molecular and environmental influences on the body.
This test represents the primary epigenetic clock used in the TruAge platform and serves as a benchmark for assessing the overall biological aging rate. It integrates genomic, lifestyle, and environmental factors to determine whether one’s biological age is younger or older than their chronological age.
While it provides valuable insight into global aging processes, interpretation should be contextualized alongside other biomarkers such as DunedinPACE or physiological health metrics.
Category: Epigenetics
Level: Advanced
Usefulness: Low
Level
Advanced
Usefulness
Low
General aging benchmark
Offers a single biological age value reflecting cumulative exposure to aging processes, lifestyle, and environment.
Research and longevity tracking
Useful for longitudinal monitoring of biological age trends over time, particularly in intervention studies.
Limited actionable precision
While informative, results do not specify which physiological systems drive accelerated or decelerated aging.
How it works
Sample collection
A small blood sample is collected and processed in a certified laboratory. DNA is extracted and prepared for analysis.
Methylation profiling
DNA methylation levels at thousands of CpG sites are quantified and compared with a reference dataset to calculate epigenetic age using the OMICm algorithm.
Measures
OMICm Biological Age
The predicted biological age based on DNA methylation data.
Age Acceleration / Deceleration
The difference between biological and chronological age; a positive score indicates faster aging.
Reliability
Reproducibility
High reproducibility under standardized lab conditions using Illumina or next-generation methylation arrays.
Sources of variance
Methylation patterns may be influenced by temporary physiological states, inflammation, or sample handling.
Limitations
Context dependence
Results must be interpreted alongside other biomarkers, such as inflammatory or metabolic markers.
Population-based reference
Predictions are derived from statistical averages and may not capture individual genetic or ethnic differences.
Frequency
Suggested cadence
Once per year or after major lifestyle interventions to assess long-term biological age trends.
Cost
Typical costs
Approximately €300–600 depending on the provider and inclusion in broader epigenetic testing panels.
Availability
Where available
Offered by TruDiagnostic and partner longevity clinics worldwide. Requires laboratory DNA methylation sequencing.
Preparation
How to prepare
No special preparation required. Avoid major infections or acute stress before blood draw for more stable results.
Interpretation
Biological age younger than chronological age
Suggests slower molecular aging and positive lifestyle influence.
Biological age older than chronological age
Indicates accelerated molecular aging; further investigation of inflammation, metabolic health, or stress exposure may be warranted.
Alternatives
Horvath or Hannum Clocks
Earlier-generation DNA methylation clocks that estimate biological age but with lower predictive power for morbidity and mortality.
DunedinPACE (TruDiagnostic)
Measures the rate of aging rather than total biological age, providing complementary information.
FAQ
Is OMICm Age clinically validated?
It is scientifically validated across large datasets but not intended as a diagnostic or predictive medical test.
Can I reverse my biological age score?
Changes can be achieved through sustained lifestyle improvements, but due to biological noise, short-term fluctuations should not be overinterpreted.
Does a younger OMICm Age mean better health?
Generally yes, but it should be viewed as a global indicator rather than proof of superior health or reduced disease risk.